These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 35101893)
1. Boosting of the SARS-CoV-2-Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine. Komissarov AA; Dolzhikova IV; Efimov GA; Logunov DY; Mityaeva O; Molodtsov IA; Naigovzina NB; Peshkova IO; Shcheblyakov DV; Volchkov P; Gintsburg AL; Vasilieva E J Immunol; 2022 Mar; 208(5):1139-1145. PubMed ID: 35101893 [TBL] [Abstract][Full Text] [Related]
2. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G Front Immunol; 2021; 12():737083. PubMed ID: 34539673 [TBL] [Abstract][Full Text] [Related]
3. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
4. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM Front Immunol; 2021; 12():742914. PubMed ID: 34659237 [TBL] [Abstract][Full Text] [Related]
5. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Rossi AH; Ojeda DS; Varese A; Sanchez L; Gonzalez Lopez Ledesma MM; Mazzitelli I; Alvarez Juliá A; Oviedo Rouco S; Pallarés HM; Costa Navarro GS; Rasetto NB; Garcia CI; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Sosa S; Bianchimano L; Rios AS; Treffinger Cienfuegos MS; Caramelo JJ; Longueira Y; Laufer N; Alvarez DE; Carradori J; Pedrozza D; Rima A; Echegoyen C; Ercole R; Gelpi P; Marchetti S; Zubieta M; Docena G; Kreplak N; Yanovsky M; Geffner J; Pifano M; Gamarnik AV Cell Rep Med; 2021 Aug; 2(8):100359. PubMed ID: 34308389 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort. Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L Front Immunol; 2022; 13():829665. PubMed ID: 35154152 [TBL] [Abstract][Full Text] [Related]
7. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation. Jeong H; Choi YM; Seo H; Kim BJ Front Immunol; 2021; 12():637654. PubMed ID: 33732258 [TBL] [Abstract][Full Text] [Related]
8. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205 [TBL] [Abstract][Full Text] [Related]
9. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2. Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298 [TBL] [Abstract][Full Text] [Related]
10. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
12. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Jahrsdörfer B; Fabricius D; Scholz J; Ludwig C; Grempels A; Lotfi R; Körper S; Adler G; Schrezenmeier H Front Immunol; 2021; 12():743422. PubMed ID: 34659239 [TBL] [Abstract][Full Text] [Related]
13. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521 [TBL] [Abstract][Full Text] [Related]
14. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR Elife; 2021 Oct; 10():. PubMed ID: 34636722 [TBL] [Abstract][Full Text] [Related]
15. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. Klingler J; Lambert GS; Itri V; Liu S; Bandres JC; Enyindah-Asonye G; Liu X; Simon V; Gleason CR; Kleiner G; Chiu HP; Hung CT; Kowdle S; Amanat F; Lee B; Zolla-Pazner S; Upadhyay C; Hioe CE Front Immunol; 2021; 12():759688. PubMed ID: 34987505 [TBL] [Abstract][Full Text] [Related]
16. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390 [TBL] [Abstract][Full Text] [Related]
17. Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Byazrova MG; Kulemzin SV; Astakhova EA; Belovezhets TN; Efimov GA; Chikaev AN; Kolotygin IO; Gorchakov AA; Taranin AV; Filatov AV Front Immunol; 2022; 13():840707. PubMed ID: 35280987 [TBL] [Abstract][Full Text] [Related]
18. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related]
19. Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia. Alessandra R; Sara C; Claudia P; Natasha G; Federica C; Chiara B; Tobia F; Stefano T; Eleonora R; Andrea M; Martin MN; Caterina UF; Nigel T; Stefania DSM; Lucia L; Chiara P J Transl Med; 2024 Aug; 22(1):755. PubMed ID: 39135151 [TBL] [Abstract][Full Text] [Related]
20. Sputnik V-Induced Antibodies against SARS-CoV-2 Variants during the Dissemination of the Gamma Variant in Venezuela. Franco C; Cornejo A; Rodríguez M; García A; Belisario I; Mayora S; Garzaro DJ; Jaspe RC; Hidalgo M; Parra N; Liprandi F; Zambrano JL; Rangel HR; Pujol FH Viruses; 2024 Sep; 16(9):. PubMed ID: 39339956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]